Combined chelation therapy with deferasirox and deferoxamine in thalassemia

A Lal, J Porter, N Sweeters, V Ng, P Evans… - Blood Cells, Molecules …, 2013 - Elsevier
Iron overload is the primary cause of mortality and morbidity in thalassemia major despite
advances in chelation therapy. We performed a pilot clinical trial to evaluate the safety and …
被引用次数：110 相关文章
[HTML] nih.gov

[HTML][HTML] Combined Chelation Therapy with Deferasirox and Deferoxamine in Thalassemia

A Lal, J Porter, N Sweeters, V Ng, P Evans… - … cells, molecules & …, 2013 - ncbi.nlm.nih.gov
Iron overload is the primary cause of mortality and morbidity in thalassemia major despite
advances in chelation therapy. We performed a pilot clinical trial to evaluate the safety and …

Combined chelation therapy with deferasirox and deferoxamine in thalassemia.

A Lal, J Porter, N Sweeters, V Ng, P Evans… - … cells, molecules & …, 2013 - escholarship.org
Iron overload is the primary cause of mortality and morbidity in thalassemia major despite
advances in chelation therapy. We performed a pilot clinical trial to evaluate the safety and …
[PDF] academia.edu

[PDF][PDF] Combined Chelation Therapy with Deferasirox and Deferoxamine in Thalassemia

A Lal, J Porter, N Sweeters, V Ng, P Evans… - Blood Cells Mol …, 2013 - academia.edu
Iron overload is the primary cause of mortality and morbidity in thalassemia major despite
advances in chelation therapy. We performed a pilot clinical trial to evaluate the safety and …

Combined chelation therapy with deferasirox and deferoxamine in thalassemia.

A Lal, J Porter, N Sweeters, V Ng, P Evans… - … Cells, Molecules & …, 2012 - europepmc.org
Iron overload is the primary cause of mortality and morbidity in thalassemia major despite
advances in chelation therapy. We performed a pilot clinical trial to evaluate the safety and …

Combined chelation therapy with deferasirox and deferoxamine in thalassemia

A Lal, J Porter, N Sweeters, V Ng… - … cells, molecules & …, 2013 - pubmed.ncbi.nlm.nih.gov
Iron overload is the primary cause of mortality and morbidity in thalassemia major despite
advances in chelation therapy. We performed a pilot clinical trial to evaluate the safety and …

Combined chelation therapy with deferasirox and deferoxamine in thalassemia

A Lal, J Porter, N Sweeters, V Ng, P Evans… - Blood Cells, Molecules …, 2013 - infona.pl
Iron overload is the primary cause of mortality and morbidity in thalassemia major despite
advances in chelation therapy. We performed a pilot clinical trial to evaluate the safety and …
[PDF] academia.edu

[PDF][PDF] Combined chelation therapy with deferasirox and deferoxamine in thalassemia

A Lal, J Porter, N Sweeters, V Ng, P Evans… - Blood Cells, Molecules …, 2013 - academia.edu
Ashutosh Lal a,⁎, John Porter b, Nancy Sweeters a, Vivian Ng a, Patricia Evans b, Lynne
Neumayr a, Gregory Kurio c, Paul Harmatz d, Elliott Vichinsky aa Hematology/Oncology …

Combined chelation therapy with deferasirox and deferoxamine in thalassemia

A Lal, J Porter, N Sweeters, V Ng, P Evans… - Blood Cells, Molecules …, 2013 - infona.pl
Iron overload is the primary cause of mortality and morbidity in thalassemia major despite
advances in chelation therapy. We performed a pilot clinical trial to evaluate the safety and …